Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells

Oumar Camara, Andreas Kavallaris, Helmut Nöschel, Matthias Rengsberger, Cornelia Jörke, Katharina Pachmann, Oumar Camara, Andreas Kavallaris, Helmut Nöschel, Matthias Rengsberger, Cornelia Jörke, Katharina Pachmann

Abstract

Background: Surgery of malignant tumors has long been suspected to be the reason for enhancement of growth of metastases with fatal outcome. This often prevented surgeons from touching the tumor if not absolutely necessary. We have shown in lung cancer patients that surgery, itself, leads to mobilization of tumor cells into peripheral blood. Some of the mobilized cells finding an appropriate niche might grow to form early metastases. Monitoring of tumor cell release during and the fate of such cells after surgery for breast cancer may help to reveal how metastases develop after surgery.

Method: We used the MAINTRAC analysis, a new tool for online observation of circulating epithelial cells, to monitor the number of epithelial cells before, 30 min, 60 min, three and seven days after surgery and during subsequent variable follow up in breast cancer patients.

Results: Circulating epithelial cells were already present before surgery in all patients. During the first 30-60 min after surgery values did not change immediately. They started increasing during the following 3 to 4 days up to thousand fold in 85% of treated patients in spite of complete resection of the tumor with tumor free margins in all patients. There was a subsequent re-decrease, with cell numbers remaining above pre-surgery values in 58% of cases until onset of chemotherapy. In a few cases, where no further therapy or only hormone treatment was given due to low risk stage, cell numbers were monitored for up to three years. They remained elevated with no or a slow decrease over time. This was in contrast to the observation in a patient where surgery was performed for benign condition. She was monitored before surgery with no cells detectable. Epithelial cells increased up to more than 50,000 after surgery but followed by a complete reduction to below the threshold of detection.

Conclusion: Frequently before but regularly during surgery of breast cancer, epithelial cells are mobilized into circulation. Part of these cells, most probably normal or apoptotic cells, are cleared from the circulation as also shown to occur in benign conditions. After resection even if complete and of small tumors, cells can remain in the circulation over long times. Such cells may remain "dormant" but might settle and grow into metastases, if they find appropriate conditions, even after years.

Figures

Figure 1
Figure 1
Positively stained gated green fluorescing cells which have been relocalized and visually analyzed. Typical pictures of such cells detected by their green fluorescing cap are shown.
Figure 2
Figure 2
Analysis of the number of circulating cells from 11 patients immediately before and 30 and 60 min after surgery.
Figure 3
Figure 3
Increase and decrease of circulating cells of 25 patients before and 3 and 6 days after surgery for breast cancer setting pre-surgery values 100%. The fat dotted line with squares represents the mean increase and decrease of all 25 patients. Two patients (one during cryotherapy and one with DCIS (fat lines) retain identical numbers during intervention.
Figure 4
Figure 4
% of pre-surgery values of recirulating cells until onset of adjuvant chemotherapy.
Figure 5
Figure 5
Numbers of longtime recirculating cells in patients without adjuvant chemotherapy. Two patients (orange and blue (DCIS) line) have now been monitored more than three years always revealing almost identical number of recirculating cells. In contrast, in a patient without a solid tumor (dotted line) who underwent surgery for a benign condition, cells returned to below the threshold of detection without further treatment.

References

    1. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330:217–220. doi: 10.1136/bmj.38314.622095.8F.
    1. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. PNAS. 2003;100:7737–7742. doi: 10.1073/pnas.1331931100.
    1. Pachmann K, Camara O, Kavallaris A, Schneider U, Schünemann S, Höffken K. Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res. 2005;7:R975–R979. doi: 10.1186/bcr1328.
    1. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10:8152–8162. doi: 10.1158/1078-0432.CCR-04-1110.
    1. Pachmann K. Long-time recirculating tumor cells in breast cancer patients. Clin Cancer Res. 2005;11:5657–5658. doi: 10.1158/1078-0432.CCR-05-0191.
    1. Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, Valagussa P, Bonadonna G. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005;16:1449–1457. doi: 10.1093/annonc/mdi280.
    1. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005;103:884–891. doi: 10.1002/cncr.20834.
    1. Braun S, Marth C. Circulating tumor cells in metastatic breast cancer-toward individualized treatment? N Engl J Med. 2004;351:824–826. doi: 10.1056/NEJMe048163.
    1. Pachmann K, Heiss P, Demel U, Tilz G. Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC) Clin Chem Lab Med. 2001;39:811–817. doi: 10.1515/CCLM.2001.134.
    1. Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, Höffken K. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med. 2005;43:617–627. doi: 10.1515/CCLM.2005.107.
    1. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003;82:199–206. doi: 10.1023/B:BREA.0000004377.12288.3c.
    1. Baines CJ. Are there downsides to mammography screening? Breast J. 2005;11:7–10. doi: 10.1111/j.1075-122X.2005.217162.x.
    1. Cserni G, Bianchi S, Boecker W, Decker T, Lacerda M, Rank F, Wells CA, European Working Group for Breast Screening Pathology Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer. 2005;103:358–367. doi: 10.1002/cncr.20760.
    1. Diaz NM, Cox CE, Ebert M, Clark JD, Vrcel V, Stowell N, Sharma A, Jakub JW, Cantor A, Centeno BA, Dupont E, Muro-Cacho C, Nicosia S. Benign Mechanical Transport of Breast Epithelial Cells to Sentinel Lymph Nodes. Am J Surg Pathol. 2004;28:1641–1645.
    1. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006;98:316–325.
    1. van Nimwegen MJ, Verkoeijen S, van Buren L, Burg D, van de Water B. Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res. 2005;65:4698–4706. doi: 10.1158/0008-5472.CAN-04-4126.
    1. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 2004;64:7336–7345. doi: 10.1158/0008-5472.CAN-04-0113.
    1. Chambers AF, George N, Naumov GN, Vantyghem SA, Tuck AB. Molecular biology of breast metastasis: Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2000;2:400–407. doi: 10.1186/bcr86.
    1. Rolle A, Günzel R, Pachmann U, Willen B, Höffken K, Pachmann K. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitore by MAINTRAC® is a predictor for relapse: A preliminary report. World J Surg Oncol. 2005;3:18. doi: 10.1186/1477-7819-3-18.
    1. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, Polzer B, Petronio M, Eils R, Klein CA. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell. 2005;8:227–239. doi: 10.1016/j.ccr.2005.08.003.
    1. Singletary SE. New approaches to surgery for breast cancer. Endocr Relat Cancer. 2001;8:265–286. doi: 10.1677/erc.0.0080265.
    1. Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D. The process of metastasisation for breast cancer. Eur J Cancer. 2003;39:1794–1806. doi: 10.1016/S0959-8049(03)00422-2.
    1. Retsky MW, Swartzendruber DE, Bame PD, Wardwell RH. Computer model challenges breast cancer treatment strategy. Cancer Invest. 1994;12:559–567.

Source: PubMed

3
Subscribe